high definition diagnostics℠

Technology Designed to Reveal More

Simoa's revolutionary digital approach to immunoassays allows single molecules to be counted, delivering a roughly 1000-fold increase in sensitivity. This remarkable sensitivity combined with full automation unlocks a world of insight into disease detection, diagnosis, and patient treatment while meeting the demands of today's laboratory.

 

Watch the Simoa video to learn more

 
 

Unprecedented Sensitivity

1000 times greater sensitivity than conventional immunoassays.
Learn More.

 

Robust Multiplexing

Improve efficiencies and stretch samples with up to 10-plex assays.
Learn More.

 

Complete Automation

Sample in, result out with an intuitive, user-friendly interface.
Learn More.

 

Quanterix News

  • Quanterix Expands Kevin Hrusovsky’s Role to CEO

    Wednesday, 04 March 2015

    LEXINGTON, MA – March 4, 2015 Quanterix Corporation, a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Chief Executive Officer (“CEO”). Mr. Hrusovsky will continue to serve as Executive Chairman of its Board of Directors.

    Read More

  • Quanterix’ Simoa Technology to Support Myriad RBM’s New Immunoassay Services

    Thursday, 05 March 2015

    LEXINGTON, MA – March 5, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), will use Quanterix’ Simoa technology to launch new ultrasensitive immunoassay services in its CLIA-certified laboratory in Austin, Texas. Using Simoa, the company will have the ability to accurately measure protein biomarkers that were previously difficult or even impossible to detect in blood samples.

    Read More